| Drug Name: | Imipramine (50-49-7) |
|---|---|
| PubChem ID: | 3696 |
| SMILES: | CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31 |
| InchiKey: | BCGWQEUPMDMJNV-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic Uptake Inhibitors, Antidepressive Agents, Central Nervous System Agents, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Psychotropic Drugs |
| Molecular Weight (dalton) | : | 280.415 |
| LogP | : | 3.875 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 6.48 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Phenytoin (57-41-0) | Drowsiness | Synergistic | imipramine inhibits the metabolism of the phenytoin by the liver, which results in its accumulation in the body. In vitro study has shown that the tricyclics can inhibit the cytochrome P450 isoenzyme CYP2C19 | Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin |
| Levodopa (59-92-7) | Hypertensive Crisis | Synergistic | Not understood | Adverse interaction of levodopa with tricyclic antidepressants |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|---|---|---|---|
| 2-Hydroxy-imipramine | Cardiotoxic | Effects of several tricyclic antidepressants on the hemodynamics and myocardial contractility of the anesthetized dogs |
This panel provides information on drug category